Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BQS7
UPID:
HEPH_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BQS7; B1AJX8; D3DVT7; E9PHN8; O75180; Q6UW45; Q9C058
Background:
Hephaestin, identified by its gene symbol Q9BQS7, plays a crucial role in iron metabolism, acting as a ferroxidase that facilitates the conversion of ferrous (II) to ferric ion (III). This process is essential for iron homeostasis and is closely linked to copper transport within the body. Hephaestin's activity is pivotal in mediating iron efflux in conjunction with ferroportin 1, ensuring proper iron distribution and preventing iron overload.
Therapeutic significance:
Understanding the role of Hephaestin could open doors to potential therapeutic strategies. Its involvement in iron and copper homeostasis positions it as a key target for addressing disorders related to metal metabolism, such as anemia and Wilson's disease. By elucidating Hephaestin's mechanisms, novel treatments for these conditions could be developed, offering hope for patients suffering from metal-related disorders.